Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Type B insulin resistance belongs to a class of diseases caused by an autoantibody to a cell surface receptor. Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women. This rare autoimmune disorder has been treated with various forms of immunosuppression with mixed success. METHODS: We describe 14 patients with type B insulin resistance referred to the National Institutes of Health, adding to an existing cohort of 24 patients. This report focuses on seven patients who were treated with an intensive combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids aimed at control of pathogenic autoantibody production. Hematological, metabolic, and endocrine parameters, including fasting glucose, glycated hemoglobin, insulin dose, lipids, and testosterone, were monitored before and after treatment. RESULTS: All seven treated patients achieved remission, defined as amelioration of hyperglycemia, discontinuation of insulin therapy, and resolution of hyperandrogenism. Glycated hemoglobin has normalized in all seven treated patients. Remission was achieved on average in 8 months from initiation of treatment. The medication regimen was well tolerated, with no serious adverse events. CONCLUSIONS: In seven patients with type B insulin resistance, standardized treatment with rituximab, cyclophosphamide, and pulse steroids results in remission of the disease. Future studies will determine whether this treatment protocol can be applied to other autoantibody/cell surface receptor disease states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
ARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P. (2002) · Medicine · doi:10.1097/00005792-200203000-00001 · Cited by 223
Cited by
Insulin resistance and PCOS: chicken or egg?
Moghetti, P., & Tosi, F. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01351-0 · Cited by 209
Insulin autoimmune syndrome: from diagnosis to clinical management
Censi, S., Mian, C., & Betterle, C. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.07.32 · Cited by 152
The treatment of hyperinsulinemic hypoglycaemia in adults: an update
On behalf of NIKE Group, Davi′, M. V., Pia, A., Guarnotta, V., Pizza, G., Colao, A., & Faggiano, A. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0536-3 · Cited by 51
“A new therapeutic protocol was reported with an intensive combination of rituximab, cyclophosphamide and pulse corticosteroids, showing after 8 months of the treatment the remission of symptoms [140].”
Background
Metadata
- Authors
- Malek, R., Chong, A. Y., Lupsa, B. C., Lungu, A. O., Cochran, E. K., Soos, M. A., Semple, R. K., Balow, J. E., & Gorden, P.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-08-01
- Volume
- 95
- Issue
- 8
- Pages
- 3641-3647
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109011155
- Cited by
- 114
- References
- 2
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies. https://app.cochat.ai/papers/10.1210/jc.2010-0167
- The paper
- Malek, R., Chong, A. Y., Lupsa, B. C., Lungu, A. O., Cochran, E. K., Soos, M. A., Semple, R. K., Balow, J. E., & Gorden, P. (2010). Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-0167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.